ClinicalTrials.gg
CompletedNCT04229277Updated Jun 20, 2024

Fast Track Diagnosis of Skin Cancer by Advanced Imaging

An interventional study of optical coherence tomography in Malignant Melanoma, Nevus, Pigmented and Basal Cell Carcinoma, sponsored by University Hospital Bispebjerg and Frederiksberg. Completed at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-20.

Sponsored by University Hospital Bispebjerg and Frederiksberg · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Sep 2019, registered Jan 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Aim of study:

To collect data for a new image-guided diagnostic algoritm, enabling the investigators to differentiate more precisely between benign and malignant pigmented tumours at the bedside. This study will include 60 patients with four different pigmented tumours: seborrheic keratosis (n=15), dermal nevi (n=15), pigmented basal cell carcinomas (n=15), and malignant melanomas (n=15), these four types of tumours are depicted in Fig.1, and all lesions will be scanned by four imaging technologies, recruiting patients from Sept 2019 to May 2020. In vivo reflectance confocal microscopy (CM) will be used to diagnose pigmented tumours at a cellular level and provide micromorphological information5;6. Flourescent CM will be applied to enhance contrast in surrounding tissue/tumours. Optical coherence tomography (OCT), doppler high-frequency ultrasound (HIFU) and photoacustic imaging (also termed MSOT, multispectral optoacustic tomography) will be used to measure tumour thickness, to delineate tumours and analyze blood flow in blood vessels. Potential diagnostic features from each lesion type will be tested. Diagnostic accuracy will be statistically evaluated by comparison to gold standard histopathology

Read the detailed description

Study design The prospective non-blinded clinical study will include with seborrheic keratosis (n=15), dermal nevi (n=15), pigmented or dark basal cell carcinomas (n=15), and malignant melanomas (n=15) referred to or diagnosed at Dept. of Dermatology, Bispebjerg Hospital. All tumours are histologically verified by skin biopsy. To explore clinical feasibility and diagnostic accuracy of four different skin imaging technologies all patients will be scanned by an experienced examiner in one 2-hour session. If patients demonstrate more than one skin tumour within the same anatomical location, all lesions will be included and scanned. Lesions in other anatomical areas of the same patient will not be included. The total extra time spend in the department to participate in this study will be approximately 2-3 hours for each patient. Only one visit is required to participate. The skin tumors in patients enrolled will subsequently be treated according to hospital and national guidelines.

Background: A bedside examination of a skin tumours using advanced imaging technology is considered a valuable future tool for Dermatologists. The investigators vision is to provide image guided skin cancer therapy to all patients with skin tumours. This study compares clinical feasibility and diagnostic accuracy of four different imaging technologies applied in a fast-track bedside analysis of various skin tumours; four different types, 2 benign and 2 malignant types.

It is also hypothesized that:

  • Due to higher resolution UHR-OCT may have higher diagnostic accuracy than C-OCT.
  • Doppler HIFU and optoacustic imaging diagnosis may be more accurate in skin tumours thicker than 1-2 mm compared to diagnosis based on OCT imaging.
  • The cellular resolution of RCM and the detailed blood flow information acquired from photoacustic imaging may supplement clinical decision making and increase diagnostic accuracy compared to only OCT or only HIFU.

Study objectives

Primary objective:

This study explores the clinical utility of four skin imaging technologies: scanning time, clinical feasibility (does the skin tumour fit into the scanning probe) and diagnostic accuracy. The investigators examine patients with four different common skin tumour types referred to Dept of Dermatology, BFH using four different advanced imaging technologies; five different tools as investigators apply two different OCT-systems.

Secondary outcome measures:

  • To measure diagnostic accuracy of index tests (OCT, RCM, HIFU and photoacoustic imaging)
  • To measure tumor size by OCT, photoacoustic imaging and HIFU
  • To explore if UHR-OCT detects features in tumors that C-OCT cannot detect.
  • To explore if information from dynamic C-OCT images of dermal blood vessels inside the skin tumour increases diagnostic accuracy
  • To explore if information from doppler ultrasound images of dermal vessels inside the tumour increases diagnostic accuracy
  • To explore if information from photoacoustic imaging of dermal vessels inside the tumour increases diagnostic accuracy
  • To report potential decreased time delay from first visit to efficient skin cancer treatment
  • To record survival rates
  • To record treatment types and number of therapeutic sessions (e.g. operations)
  • To report potential adverse device events
  • To report patient satisfaction of scanning procedures

Evaluation of skin tumours All skin tumours will be evaluated clinically, by two different OCT systems (C-OCT and UHR-OCT), by RCM, by photoacoustic imaging and doppler HIFU. Skin biopsies will be performed according to standard hospital procedures. Skin punch biopsies from skin tumours are required for treatment planning and is not part of this research project. Accordingly, a skin biopsy will be performed as part of the treatment plan independent of whether the patient is recruited or not.

Imaging Technologies In vivo reflectance confocal microscopy (CM) will be used to diagnose pigmented tumours at a cellular level and provide micromorphological information5;6. Flourescent CM will be applied to enhance contrast in surrounding tissue/tumours. Optical coherence tomography (OCT), doppler high-frequency ultrasound (HIFU) and photoacustic imaging (also termed MSOT, multispectral optoacustic tomography) will be used to measure tumour thickness, to delineate tumours and analyze blood flow in blood vessels. Potential diagnostic features from lesion types will be tested. Diagnostic accuracy will be statistically evaluated by comparison to gold standard histopathology The imaging methods OCT, RCM and doppler ultrasound, are technologies that are routinely used in the clinic at Dept of Dermatology, BFH and all investigators are highly trained in using the scanners. The UHR-OCT is a prototype and the photoacoustic system is a brand-new clinical device. OCT, RCM and ultrasound examinations are performed in a darkened room. The images of all patients will be saved in a digital archiving computer system for subsequent scoring and further evaluation.

02

Conditions studied

  • Malignant Melanoma
  • Nevus, Pigmented
  • Basal Cell Carcinoma
  • Seborrheic Keratosis
03

In context

Melanoma

3,073 studies on the registry are indexed under Melanoma; 529 are open to participants now.

This study's enrollment of 41 is close to the median of 38 across 2,400 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

University Hospital Bispebjerg and Frederiksberg is the lead sponsor of 69 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 60 Patients with histologically verified: seborrheic keratosis 15 in total, dermal nevi 15 in total, pigmented BCC in total, and malignant melanomas 15 in total on areas of the body where scanning is feasible with all five systems
  2. Patients with skin tumours clinically suspicious of one of the four lesions mentioned in (1), that are not yet biopsied, if the patient is willing to undergo a skin biopsy from the suspicious lesion
  3. > 18 years of age at baseline
  4. Legally competent, able to give verbal and written consent
  5. Communicate in Danish verbally as well as in writing
  6. Subject in good general health, is willing to participate and able to give informed consent and can comply with protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with other skin diseases in the skin area of interest
  2. Individuals who´s skin tumour is not accessible for imaging e.g. inside the ear, inside nostrils, on eyelids
  3. Subjects who will not undergo a skin biopsy after imaging of the suspicious tumour clinically diagnosed as BCC
  4. Pregnancy
  5. Women of child-bearing potential not using a contraceptive agent at the time of inclusion
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Other
    in tumours

    consecutive enrollment of newly referred skin tumour patients

    Diagnostic Test: optical coherence tomography

Interventions

  • Diagnostic testoptical coherence tomography

    comparison of four imaging technologies in skin tumour diagnosis

    Also known as: photoacoustic imaging, in vivo confocal microscopy, doppler ultrasound

06

What researchers measure

Primary outcomes

  1. diagnostic accuracy of the four methods imaging methods compared to histopathology of skin tumours.

    Sensitivity is expressed in percentage and defines the proportion of true positive subjects with the disease in a total group of subjects with the disease (TP/TP+FN). Sensitivity is defined as the probability of getting a positive test result in subjects with the disease (T+\|B+). Specificity is a measure of diagnostic test´s accuracy, complementary to sensitivity. It is defined as a proportion of subjects without the disease with negative test result in total of subjects without disease (TN/TN+FP). Sensitivity and specificity are reported in percent

    Time frame: 6-12 months

Secondary outcomes

  1. tumour thickness

    in millimeters

    Time frame: 6-12 months

  2. survival rates

    in number of months

    Time frame: 12 months

  3. blood flow in skin tumours

    expressed in arbitrary units in OCT volume scans and in volume densities/second in doppler ultrasound images

    Time frame: 6-12 months

  4. To report potential decreased time delay from first visit to efficient skin cancer treatment

    Expressed as duration of time from diagnosis till initial treatment in number of days

    Time frame: 12 months

  5. To record treatment types and number of therapeutic sessions (e.g. operations)

    For each study participant treatment types are listed in numerical numbers and so is the number of treatment sessions counted and listed for each individual participant in this trial

    Time frame: 12 months

  6. To report patient satisfaction of scanning procedures

    A questionnaire with qualitative questions (How did you like being scanned?) and quantitative questions: on a scale from 0-10 how painful was the scanning procedure)

    Time frame: 6-12 months

07

Study locations

1 site
  • Dept of Dermatology
    Copenhagen, dk-2400, Denmark
08

References and documents

Individual participant data

Plan to share: No — The images file data will be very large and will be situated on the hospital server. We cannot legally share these files.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04229277
Lead sponsor
University Hospital Bispebjerg and Frederiksberg
Responsible party
Mette Mogensen (MD, PhD, Ass. Prof., Chief Consultant, University Hospital Bispebjerg and Frederiksberg) — Principal investigator
First posted
Jan 18, 2020
Start date
Sep 9, 2019
Primary completion
Mar 22, 2021
Completion
Jun 1, 2021
Last update
Jun 20, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion